A clinical pharmacological experimental research analysis of the evidence-based rational pharmacotherapeutics of pefloxacin and newer quinolones

Moumita Hazra

doi:10.18203/2319-2003.ijbcp20223362

Authors

Moumita Hazra Department of Pharmacology, Clinical Pharmacology and Molecular Pharmacology, Narayana Medical College, Narayana Hospitals, Nellore, Andhra Pradesh, India Department of Pharmacology, Clinical Pharmacology and Molecular Pharmacology, Mamata Medical College, Mamata Hospitals, Khammam, Telangana, India Department of Pharmacology, Clinical Pharmacology and Molecular Pharmacology, Rama Medical College Hospital and Research Centre, Rama University, Kanpur, Uttar Pradesh, India Dr. Moumita Hazra’s Polyclinic and Diagnostic Centre, Hazra Nursing Home, Hazra Polyclinic and Diagnostic Centre, Dr. Moumita Hazra’s Academic Centre and Educational Centre, Howrah, West Bengal, India Department of Pharmacology, Clinical Pharmacology, Clinical Pathology and Pathology, J. J. M. Medical College and Hospitals, Chigateri General Hospital, Davangere, Karnataka, India Department of Pharmacology and Clinical Pharmacology, K. D. Medical College Hospital and Research Center, Mathura, Uttar Pradesh, India Department of Pharmacology and Clinical Pharmacology, Shri Ramkrishna Institute of Medical Sciences and Sanaka Hospitals, Howrah, West Bengal, India Global Institute of Stem Cell Therapy and Research, Institute of Regenerative Medicine University Institutes, Hospitals and Laboratories, New Delhi, India Quality Management and Clinical Excellence, Department of Medical Administration, Fortis Hospitals, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20223362

Keywords:

Rational pharmacotherapeutics, Pefloxacin, Newer quinolones, Bacterial conjunctivitis

Abstract

Background: Pefloxacin is a newer broad-spectrum bactericidal fluoroquinolone antibiotic, with superior antibacterial activity in vivo against pathogenic ocular gram-negative and anaerobic microorganisms and better pharmacokinetic properties.

Methods: 100 bacterial conjunctivitis patients were prescribed topical pefloxacin 0.3% ophthalmological drops monotherapy, 2 drops in each eye after every 3 hours for 2 days, and 2 drops in each eye after every 6 hours for next 5 days. The overall recovery of the patients was clinically examined and assessed. The patients who did not recover completely with 0.3% pefloxacin monotherapy ophthalmological drops, were administered topical pefloxacin 0.3% ophthalmological drops, 2 drops in each eye after every 6 hours for the next 3 days, as combination therapy, with other required ophthalmological eye drops, depending on the prognostic follow-up, on days 0, 3, 5, 7, 10, 15, 30, and on further follow-ups. The evidence-based rational pharmacotherapeutic patient percentage topical application requirements of 0.3% pefloxacin ophthalmological drops monotherapy and subsequent combination therapy for complete recovery from bacterial conjunctivitis was thoroughly analysed and assessed.

Results: In this study, the patient percentage topical application requirements of pefloxacin 0.3% ophthalmological drops monotherapy and combination therapy in bacterial conjunctivitis patients showed that 93% patients had completely recovered with pefloxacin monotherapy, and 7% patients required pefloxacin combination therapy for complete recovery. The evidence-based rational pharmacotherapeutics of newer quinolones, in global multi-centre tertiary care hospitals, was also well characterized and analytically described.

Conclusions: Therefore, 93% patients had completely recovered with the ocular antibiotic pefloxacin 0.3% ophthalmological drops monotherapy, and 7% patients required pefloxacin combination therapy for complete recovery. The evidence-based rational pharmacotherapeutics of newer quinolones was also distinctly delineated.

Metrics

Metrics Loading ...

Author Biography

Moumita Hazra, Department of Pharmacology, Clinical Pharmacology and Molecular Pharmacology, Narayana Medical College, Narayana Hospitals, Nellore, Andhra Pradesh, India Department of Pharmacology, Clinical Pharmacology and Molecular Pharmacology, Mamata Medical College, Mamata Hospitals, Khammam, Telangana, India Department of Pharmacology, Clinical Pharmacology and Molecular Pharmacology, Rama Medical College Hospital and Research Centre, Rama University, Kanpur, Uttar Pradesh, India Dr. Moumita Hazra’s Polyclinic and Diagnostic Centre, Hazra Nursing Home, Hazra Polyclinic and Diagnostic Centre, Dr. Moumita Hazra’s Academic Centre and Educational Centre, Howrah, West Bengal, India Department of Pharmacology, Clinical Pharmacology, Clinical Pathology and Pathology, J. J. M. Medical College and Hospitals, Chigateri General Hospital, Davangere, Karnataka, India Department of Pharmacology and Clinical Pharmacology, K. D. Medical College Hospital and Research Center, Mathura, Uttar Pradesh, India Department of Pharmacology and Clinical Pharmacology, Shri Ramkrishna Institute of Medical Sciences and Sanaka Hospitals, Howrah, West Bengal, India Global Institute of Stem Cell Therapy and Research, Institute of Regenerative Medicine University Institutes, Hospitals and Laboratories, New Delhi, India Quality Management and Clinical Excellence, Department of Medical Administration, Fortis Hospitals, India

1Associate Professor, Head of Department In Charge, Department of Pharmacology, Mamata Medical College, Mamata Hospitals, Telangana, India;
2Medical Director, Consultant Multi-Specialist Clinical Pharmacological Physician, Consultant Clinical Pathologist, Medical Superintendent, Principal, Medical Academics and Clinical Research Director, Dr. Moumita Hazra’s Polyclinic And Diagnostic Centre, Hazra Nursing Home, Hazra Polyclinic And Diagnostic Centre, Dr. Moumita Hazra’s Academic Centre, Dr. Moumita Hazra’s Educational Centre, West Bengal, India, World;
3Consultant Pathologist, Laboratory Supervisor, Mahuya Diagnostic Centre and Doctors’ Chamber, West Bengal, India.

References

Hazra M. A comparative study on the pharmacovigilance scoring of causality assessment grading and staging of topical pharmacotherapy of ofloxacin 0.3% ophthalmic solution in bacterial conjunctivitis and ofloxacin 0.3% otic solution in otitis externa. Int J Basic Clin Pharmacol. 2022;11:173-80.

Hazra M. A rational pharmacotherapeutic study of comparative safety among topical anti anti-acne 1% nadifloxacin monotherapy, 0.1% adapalene monotherapy, 0.025% tretinoin monotherapy, 1% nadifloxacin and 0.1% adapalene combination therapy and 1% nadifloxacin and 0.025% tretinoin combination therapy, in mild to moderate acne vulgaris, in tertiary care hospitals. Int J Basic Clin Pharmacol. 2019;8(9):1959-65.

Hazra M. A rational pharmacotherapeutic study in pharmacovigilance: a comparative assessment of safety between topical 1% nadifloxacin and 0.1% adapalene combination therapy and topical 1% nadifloxacin and 0.025% tretinoin combination therapy, in mild to moderate acne, in tertiary care hospitals, in India. J Evid Based Med Healthc. 2019;6(35):2366-71.

Hazra M, Geetha M, Somashekhar HS, Murugesh SB. A comparative study on the efficacy of topical 1% nadifloxacin and 0.1% adapalene combination therapy with 1% clindamycin and 0.1% adapalene combination therapy, in mild to moderate acne, in a tertiary care hospital. Indian J Pharmacol. 2014;46(1):S73.

Hazra M. Newer Quinolones: The Novel Pharmacotherapeutics. Hazra M, editor. New Delhi, India: AkiNik Publications. 1st edition. 2022.

Yadav S, Parvez N. A comparative evaluation of 0.3% eye drops and in situ forming gel of pefloxacin mesylate in experimentally induced pseudomonas conjunctivitis. Continental J Pharmacol Toxicol Res. 2008;2:1-5.

Brar RK, Jyoti U, Patil RK, Patil HC. Fluoroquinolone antibiotics: an overview. Adesh Univ J Med Sci Res. 2020;2(1):26-30.

Assar S, Nosratabadi R, Azad HK, Masoumi J, Mohamadi M, Hassanshahi G. A review of immunomodulatory effects of fluoroquinolones. Immunol Invest. 2020;1-20.

Mohammed HHH, Abuo-Rahma GEAA, Abbas SH, Abdelhafez ESMN. Current trends and future directions of fluoroquinolones. Curr Med Chem. 2019;26(17):3132-49.

Pradhan S, Prajna NV. Topical fluoroquinolones: current perspectives. DJO. 2015;25:267-71.

Fan KC, Lin J, Yannuzzi NA, Al-Khersan H, Patel NA, Maestre-Mesa J, et al. In vitro susceptibilities of methicillin-susceptible and resistant staphylococci to traditional antibiotics compared to a novel fluoroquinolone. J Ophthalmic Inflamm Infect. 2020;10(1):9.

Pham TDM, Ziora ZM, Blaskovich MAT. Quinolone antibiotics. Medchemcomm. 2019;10(10):1719-39.

Yan A, Bryant EE. Quinolones. In: Stat Pearls. Treasure Island (FL): Stat Pearls Publishing. 2020.

Shankarrao PR, Supriya M, Sugave RV, Patil B, Priyanka K. Formulation and evaluation of in situ gel containing pefloxacin mesylate. World J Pharm Res. 2017;6(07):1236-50.

Kovoor TA, Kim AS, McCulley JP, Cavanagh HD, Jester JV, Bugde AC, et al. Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo Confocal Microscopy. Eye Contact Lens. 2004;30(2):90-4.

Vajpayee RB, Sharma N, Verma B, Vajpayee M, Gupta SK, Satpathy G, et al. Topical pefloxacin in bacterial keratitis. Int Ophthalmol. 1998;22:47-51.

Garcia-Prats AJ, Draper HR, Thee S, Dooley KE, McIlleron HM, Seddon JA, et al. Pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis. Antimicrob Agents Chemother. 2015;59(10):6073-9.

World Health Organization. Fact sheet: Differences among fluoroquinolones in the treatment of MDR-TB. Geneva, Switzerland: World Health Organization. 2020. Available at: https://www.archives.who.int. Accessed on 21 September 2022.

Yadav V, Talwar P. Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: an underestimated truth. Biomed Pharmacother. 2019;111:934-46.

Idowu T, Schweizer F. Ubiquitous nature of fluoroquinolones: the oscillation between antibacterial and anticancer activities. Antibiotics. 2017;6(4):26.

Gao Y, Shang Q, Li W, Guo W, Stojadinovic A, Mannion C, et al. Antibiotics for cancer treatment: a double-edged sword. J Cancer. 2020;11(17):5135-49.

Karampela I, Dalamaga M. Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19? Arch Med Res. 2020;51(7):741-2.

Kasabri V, Arabiyat S, Al-Hiari Y, Zalloum H, Almaliti J, Telfah A, et al. Fluoroquinolones as a potentially novel class of antidiabesity and antiproliferative compounds: synthesis and docking studies. Can J Chem. 2020;98(10):635-45.

Lodise T, Corey R, Hooper D, Cammarata S. Safety of delafloxacin: focus on adverse events of special interest. Open Forum Infect Dis. 2018;5(10):ofy220.

Pullman J, Gardovskis J, Farley B, Sun E, Quintas M, Lawrence L, Ling R, Cammarata S; PROCEED Study Group. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a phase 3, double-blind, randomized study. J Antimicrob Chemother. 2017;72(12):3471-80.

McCurdy S, Lawrence L, Quintas M, Woosley L, Flamm R, Tseng C, Cammarata S. In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and non-susceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2017;61(9):e00772-17.

Mogle BT, Steele JM, Thomas SJ, Bohan KH, Kufel WD. Clinical review of delafloxacin: a novel anionic fluoroquinolone. J Antimicrob Chemother. 2018;73(6):1439-51.

Manosuthi W, Wiboonchutikul S. Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis. Springerplus. 2016;5:410.

Shetty N, Wilson AP. Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2000;46(4):633-8.

Lubasch A, Erbes R, Mauch H, Lode H. Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy. Eur Respir J. 2001;17(4):641-6.

Park HS, Oh SH, Kim HS, Choi DR, Kwak JH. Antimicrobial activity of zabofloxacin against clinically isolated Streptococcus pneumoniae. Molecules. 2016;21(11):1562.

Kocsis B, Domokos J, Szabo D. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob. 2016;15(1):34.

Kocsis B, Szabo D. Zabofloxacin for chronic bronchitis. Drugs Today (Barc). 2016;52(9):495-500.

Chalhoub H, Harding SV, Tulkens PM, Van Bambeke F. Influence of pH on the activity of finafloxacin against extracellular and intracellular Burkholderia thailandensis, Yersinia pseudotuberculosis and Francisella philomiragia and on its cellular pharmacokinetics in THP-1 monocytes. Clin Microbiol Infect. 2020;26(9):1254.

McKeage K. Finafloxacin: first global approval. Drugs. 2015;75(6):687-93.

Bartoletti R, Cai T, Perletti G, M E Wagenlehner F, Bjerklund Johansen TE. Finafloxacin for the treatment of urinary tract infections. Expert Opin Investig Drugs. 2015;24(7):957-63.

Rodrigues J, Ramani A, Mondarkar S, Nazareth M, Sobti V, Krishnaprasad KD. Use of garenoxacin: a new generation antibiotic for surgical infections. Int J Basic Clin Pharmacol. 2015;4:144-7.

Wren C, Bell E, Eiland LS. Ozenoxacin: a novel topical quinolone for impetigo. Ann Pharmacother. 2018;52(12):1233-7.

Hebert AA, Rosen T, Lopez NA, Zsolt I, Masramon X. Safety and efficacy profile of ozenoxacin 1% cream in pediatric patients with impetigo. Int J Womens Dermatol. 2019;6(2):109-15.

Tabara K, Tamura R, Nakamura A, Mori S, Kitano T, Fujikawa K, Fujikawa M, Okamoto K, Kanayama S, Uratsuji H, Ikeda F, Matsumoto T. Anti-inflammatory effects of ozenoxacin, a topical quinolone antimicrobial agent. J Antibiot. 2020;73:247-54.

Farrell DJ, Liverman LC, Biedenbach DJ, Jones RN. JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains. Antimicrob Agents Chemother. 2011;55(7):3631-4.

Jones TM, Johnson SW, Di Mondi VP, Wilson DT. Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Infect Drug Resist. 2016;9:119-28.

Bhatt PR, Scaiola A, Loughran G, Leibundgut M, Kratzel A, Meurs R, et al. Structural basis of ribosomal frameshifting during translation of the SARS-CoV-2 RNA genome. Science. 2021;372(6548):1306-13.

Sun Y, Abriola L, Niederer RO, Pedersen SF, Alfajaro MM, Silva Monteiro V, et al. Restriction of SARS-CoV-2 replication by targeting programmed -1 ribosomal frameshifting. Proc Natl Acad Sci USA. 2021;118926:e2023051118.

Park JH, Yamaguchi T, Ouchi Y, Koide K, Mori S, Kim H, et al. WQ-3810 inhibits DNA gyrase activity in ofloxacin-resistant Mycobacterium leprae. J Infect Chemother. 2020;26(4):335-42.

Ouchia Y, Mukai T, Koide K, Yamaguchia T, Park JH, Kim H, et al. WQ-3810: A new fluoroquinolone with a high potential against fluoroquinolone-resistant Mycobacterium tuberculosis. Tuberculosis. 2020;120:101891.

Adis Insight. Lascufloxacin – Kyorin Pharmaceutical, 2021. Available at: https://www.adisinsight. springer.com/drugs/800035339/. Accessed on 09 December 2021.

Murata M, Kosai K, Yamauchi S, Sasaki D, Kaku N, Uno N, et al. In vitro activity of lascufloxacin against Streptococcus pneumoniae with mutations in the quinolone resistance-determining regions. Antimicrob Agents Chemother. 2018;62(4):e01971-17.

Yamagishi Y, Matsukawa Y, Suematsu H, Mikamo H. In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group. Anaerobe. 2018;54:61-4.